NanoString Technologies Inc. Secures Option From the Broad Institute for Exclusive Worldwide License of Liver Cancer Gene Signature

Published: Apr 17, 2013

SEATTLE--(BUSINESS WIRE)--NanoStringĀ® Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that it has secured an option to an exclusive worldwide license for a 186-gene signature that could be used to determine the prognosis of patients diagnosed with the most common type of liver cancer, hepatocellular carcinoma (HCC), or with hepatitis C-related early-stage cirrhosis. HCC is the third leading cause of cancer mortality worldwide and Hepatitis C cirrhosis-related HCC is the most rapidly increasing cause of cancer related death in the United States.

Back to news